Event
Date: Wednesday, May 21, 2025
Event Time: 1:00 - 2:00 pm EST
Please Note:
All times are Eastern. This webinar will begin at 1:00 pm Eastern / 12:00 pm Central / 11:00 am Mountain / 10:00 am Pacific.
Description
Topline data from INHALE-3, a recent head-to-head study of AFREZZA vs Usual Care (multiple daily injections* [MDI] and automated insulin delivery [AID]) in adults with type 1 diabetes. AFREZZA is the only rapid-acting inhaled mealtime insulin indicated to improve glycemic management in adult patients with diabetes mellitus.
*Includes non-automated pumps
Sponsor
This webinar is sponsored by MannKind.
Intended Audience
This activity is designed for diabetes care and education specialists, including nurses, dietitians, pharmacists, PAs, physicians, and other health care providers interested in staying up to date on current practices of care for people with diabetes and other related conditions.
Disclaimer
There is no CE/CME credit for this activity.